Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis
A case-control study

Shereen Farghaly, MDa,∗, Mohammed Badedi, MDb, Rehab Ibrahim, MDb, Murad H. Sadhan, MDb, Aymn Alamoudi, BScd, Awaji Alnami, MDd, Abdulrahman Muhajir, MDd

Abstract
The development of pulmonary fibrosis is a rare complication of the novel coronavirus disease 2019 (COVID-19). Limited information is available in the literature about that, and the present study aimed to address this gap.

This case-control study included 64 patients with post-COVID-19 pulmonary fibrosis who were hospitalized for COVID-19. The percentage of patients aged ≥65 years (44%) who demised was higher than those who survived (25%). Male patients (62%) had higher mortality than female patients (37%). The most frequently reported clinical symptoms were shortness of breath (98%), cough (91%), and fever (70%). Most COVID-19 patients with pulmonary fibrosis (81%) were admitted to an intensive care unit (ICU), and 63% required mechanical ventilation. Bilateral lung infiltrates (94%), “ground glass” opacity (91%), “honeycomb” lung (25%), and pulmonary consolidation (9%) were commonly identified in COVID-19 patients with pulmonary fibrosis who survived. The findings for computed tomography and dyspnea scale were significantly higher in severe cases admitted to the ICU who required mechanical ventilation. A higher computerized tomography score also correlated significantly with a longer duration of stay in hospital and a higher degree of dyspnea. Half of the COVID-19 patients with pulmonary fibrosis (50%) who survived required oxygen therapy, and those with “honeycomb” lung required long-term oxygen therapy to a far greater extent than others. Cox regression revealed that smoking and asthma were significantly associated with ICU admission and the risk of mortality.

Post-COVID-19 pulmonary fibrosis is a severe complication that leads to permanent lung damage or death.

Abbreviations: ARDS = acute respiratory distress syndrome, BMI = body mass index, CIs = confidence intervals, COVID-19 = coronavirus disease 2019, CT = computerized tomography, HRs = hazard ratios, ICU = intensive care unit, ILD = interstitial lung disease, SD = standard deviation.

Keywords: acute respiratory syndrome coronavirus 2, coronavirus disease 2019, lung fibrosis, pulmonary fibrosis

1. Introduction
Pulmonary fibrosis is an interstitial lung disease (ILD) that is characterized by progressive scarring of the lung tissue, impacting lung function, and leading to impaired gas exchange and difficulty breathing.[1] Currently, the incidence of pulmonary fibrosis is increasing significantly.[2] The development of pulmonary fibrosis is associated with many risk factors, such as aging, smoking, genetic predisposition, and exposure to occupational dust and asbestos.[3] The risk of mortality is increased in patients with pulmonary fibrosis owing to a lack of effective therapies to halt disease progression.[4] Pulmonary fibrosis has been linked to viral pneumonia, such as coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, it is thought to be uncommon.[5,6] COVID-19 may cause atypical pneumonia that progresses to acute lung injury and acute respiratory distress syndrome (ARDS). The symptoms associated with COVID-19 range from mild upper respiratory tract involvement to severe ARDS requiring long-term oxygen therapy due to pulmonary fibrosis.[7] The risk of mortality in COVID-19 patients with pulmonary fibrosis increases as pulmonary fibrosis is a progressive disease that leads to respiratory failure and is associated with a poor prognosis; lung transplantation is the only treatment demonstrated to improve outcomes.[8] To the best of our knowledge, very few published papers have reported on the clinical characteristics of patients with post-COVID-19 pulmonary fibrosis[9–11]; thus, there is a need to increase the available evidence in this regard, particularly in Saudi Arabia whose population has different culture, genetic, and ethnic factors. In addition, the clinical characteristics of patients with post-COVID-19 pulmonary fibrosis in Jazan Province, Saudi Arabia,
have not yet been evaluated. Thus, the current study aimed to address this gap with assessment of clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis among hospitalized Saudi patients in Jazan, Saudi Arabia.

2. Methodology

2.1. Study design and setting

Jazan Region, located in southwestern Saudi Arabia, is characterized by a relatively homogenous population with similar ethnic and socioeconomic characteristics. This case-control study included 64 patients who were hospitalized for COVID-19 between June 1, 2020 and October 31, 2020, at King Fahad Central Hospital, Jazan Province, Saudi Arabia. The 64 patients who were hospitalized during the mentioned period, developed pulmonary fibrosis post-COVID-19. We distributed them as 32 survived patients (as cases) matched with 32 deceased patients (as controls), with a ratio 1:1 as we interested to assess clinical characteristics of post-COVID-19 pulmonary fibrosis between the survived and deceased patients rather than assessing the mortality rate. Survived patients were followed-up for 6 months. Because of the development of pulmonary fibrosis post-COVID-19 is rare, we included only 64 patients during a specific period, and this could be a limitation of sample size.

Following the guidelines of the Saudi Center for Disease Prevention and Control,[15] a diagnosis of COVID-19 was confirmed by the identification of viral RNA in nasopharyngeal swab samples using real-time reverse transcription polymerase chain reaction (LightCycler 480 Instrument II, Roche). The Jazan Health Ethics Committee (reference number H-10-Z-073) granted ethical approval (no. 2047) for the study to be conducted. The research complied with the Declaration of Helsinki. Consent was waived as the data were anonymous and collected retrospectively (secondary data).

2.2. Data collection

The data were collected retrospectively from medical records and included information about the patients’ age, sex, smoking history, comorbidities, clinical symptoms, laboratory test results, radiological findings, need for intensive care unit (ICU) admission, need for mechanical ventilation support, hospitalization duration, development of complications, and outcomes (recovery or death). Major comorbidities and chronic diseases included diabetes, hypertension, cardiovascular disease, kidney disease, obesity, tuberculosis, chronic obstructive pulmonary disease, and asthma. The most prevalent clinical symptoms of COVID-19 were fever, cough, sputum, hemoptysis, dyspnea, chest pain, diarrhea, and loss of smell. Laboratory tests were performed to assess the complete blood count, C-reactive protein, erythrocytes sedimentation rate, d-dimer, ferritin levels. The radiological investigations included chest X-ray and a computerized tomography (CT) scan. The dates of COVID-19 diagnosis, hospital admission, and death were also recorded. Disease severity was categorized according to the World Health Organization guidelines.[16] Severe cases were defined as those with oxygen saturation of \( \leq 90\% \), a respiratory rate of \( \geq 30 \) breaths per minute, and signs of severe respiratory distress. The survival time during hospitalization (i.e., the hospitalization duration) was defined as the period between hospital admission and recovery or death. The disease duration (in days) was defined as the period between the manifestation of clinical symptoms of COVID-19 and recovery or death. The criteria for recovery were based on the guidelines of the Ministry of Health, Saudi Arabia. Recovery was considered to have occurred when at least 3 days had passed after the resolution of fever and respiratory symptoms along with 2 negative polymerase chain reaction results obtained \( \geq 24 \) hours apart; alternatively, at least 10 days had to have passed since symptom onset.[17]

2.3. Inclusion and exclusion criteria

This study included patients who developed pulmonary fibrosis after testing positive for COVID-19. A diagnosis of lung fibrosis was made based on persistent respiratory symptoms following the initial recovery phase of acute infection (defined as 4 weeks after the onset of infection) with ILD using high-resolution CT and no previous history of ILD.[18] Pregnant women and patients with a previous history of ILD were excluded from the study.

2.4. Chest CT scan

With the patients in the supine position, CT of the chest was performed without intravenous contrast using a 64-channel multidetector CT scanner (Siemens Medical Solutions, Forchheim, Germany) (i.e., an Aquilion scanner with 4 x 1 mm collimation [120 kV]). The transverse images were reconstructed to 0.55 to 0.75 mm. A CT scan was carried out at discharge and at the first, third, and sixth months after discharge for survived patients. The CT score was calculated to evaluate the degree of lung involvement in patients at discharge and follow-up.[19] The score was determined by dividing the lung into 5 lung lobes; each affected lobe was scored on a scale of 0 to 5, with 0, 1, 2, 3, 4, and 5 indicating no involvement, 6% involvement, 5% to 25% involvement, 26% to 49% involvement, 50% to 75% involvement, and >75% involvement, respectively. The total CT score was the sum of the lobar scores, and it ranged from 0 to 25. The CT images were reviewed by a radiologist who was blinded to the current study.

2.5. Management plan

The patients with COVID-19 were managed according to the COVID-19 protocol approved by the Saudi Ministry of Health.[20] The patients with post-COVID pulmonary fibrosis were discharged and prescribed oral prednisolone (1 mg/kg for 2 weeks) with gradual tapering, inhaled corticosteroids, anti-coagulants, and vitamins.

2.6. Data analysis

Data entry and analysis were performed using the Statistical Package for the Social Sciences software. Categorical variables are presented as percentages, while continuous variables are presented as the mean ± standard deviation (SD) for normally distributed variables and as the mean ± standard error of the mean for non-normally distributed variables. The chi-square test was used to detect any significant associations between categorical variables. Correlation between 2 continuous variables was assessed using Pearson correlation coefficient. The independent samples t test and Mann–Whitney U test were used to compare the differences in mean values of normal and non-normal variables, respectively, between groups (adjusted for sex.
age, and body mass index [BMI]). The paired sample t test used to determine the mean difference between 2 measurements at 2 different times (pre- and post). Cox regression analyses were used to determine hazard ratios (HRs) for the outcomes with 95% confidence intervals (CIs) and adjusted age, sex, BMI. Significance was set at \( P < .05 \).

3. Results

3.1. Demographic characteristics and comorbidities

Table 1 shows the demographic characteristics and comorbidities of COVID-19 patients with pulmonary fibrosis according to sex and survival status. The percentage of patients aged \( \geq 65 \) years (44%) who demised was higher than that of those who survived (25%). However, a significant association was not identified between age and mortality risk in COVID-19 patients with pulmonary fibrosis (\( P = .204 \) (Table 1)). The mean age of the overall study population was 59 ± 13.7 years (a range of 23–89 years). The mean age of the surviving patients was 56 years (SD = 11.2) and that of deceased patients, 62 years (SD = 15.5). The proportion of male COVID-19 patients with pulmonary fibrosis (72%) was higher than that of the female patients (28%). In addition, a higher number of male patients (62%), compared with female patients (37%), died of COVID-19 (Table 1). Smoking was significantly associated with an increased risk of mortality in COVID-19 patients with pulmonary fibrosis (\( P < .001 \) (Table 1). The most common comorbidities identified were hypertension (66%), diabetes mellitus (66%), obesity (42%), asthma (15%), heart disease (10%), kidney disease (3%), tuberculosis (2%), and chronic obstructive pulmonary disease (2%). Mortality in COVID-19 patients with pulmonary fibrosis and asthma was more than double that in COVID-19 patients with other comorbidities (odds ratio = 2.5, \( P = .001 \) (Table 1).

### Table 1

| Variables               | Overall (\( N = 64 \)) | Survived (\( N = 32 \)) | Deceased (\( N = 32 \)) | \( P \) |
|-------------------------|-------------------------|-------------------------|-------------------------|---------|
| Age                     |                         |                         |                         |         |
| 23–45                   | 7 (10.9%)               | 5 (15.6%)               | 2 (6.2%)                | .204    |
| 46–64                   | 35 (54.7%)              | 19 (59.4%)              | 16 (50.0%)              |         |
| 65–89                   | 22 (34.4%)              | 8 (25.0%)               | 14 (43.8%)              |         |
| Sex                     |                         |                         |                         |         |
| Male                    | 46 (71.9%)              | 26 (81.2%)              | 20 (62.5%)              | .095    |
| Female                  | 18 (28.1%)              | 6 (18.8%)               | 12 (37.5%)              |         |
| Smoking                 |                         |                         |                         |         |
| Non-smoker              | 40 (66.7%)              | 28 (87.5%)              | 12 (37.5%)              | \(< .001 \)* |
| X-smoker                | 8 (13.3%)               | 0                       | 8 (25.0%)               |         |
| Smoker                  | 12 (20.0%)              | 4 (12.5%)               | 12 (37.5%)              |         |
| Diabetes                |                         |                         |                         |         |
| No                      | 22 (34.4%)              | 12 (37.5%)              | 10 (31.2%)              | .599    |
| Yes                     | 42 (65.6%)              | 20 (62.5%)              | 22 (68.8%)              |         |
| Hypertension            |                         |                         |                         |         |
| No                      | 22 (34.4%)              | 12 (37.5%)              | 10 (31.2%)              | .599    |
| Yes                     | 42 (65.6%)              | 20 (62.5%)              | 22 (68.8%)              |         |
| Obesity                 |                         |                         |                         |         |
| No                      | 37 (57.8%)              | 19 (59.4%)              | 18 (56.2%)              | .802    |
| Yes                     | 27 (42.2%)              | 13 (40.6%)              | 14 (43.8%)              |         |
| Heart disease           |                         |                         |                         |         |
| No                      | 58 (90.6%)              | 28 (87.5%)              | 30 (93.8%)              | .391    |
| Yes                     | 6 (9.4%)                | 4 (12.5%)               | 2 (6.2%)                |         |
| Kidney disease          |                         |                         |                         |         |
| No                      | 62 (96.9%)              | 32 (100.0%)             | 30 (93.8%)              | .151    |
| Yes                     | 2 (3.1%)                | 0                       | 2 (6.2%)                |         |
| Asthma                  |                         |                         |                         |         |
| No                      | 54 (84.4%)              | 32 (100.0%)             | 22 (68.8%)              | \(< .001 \)* |
| Yes                     | 10 (15.6%)              | 0                       | 10 (31.2%)              |         |
| Tuberculosis            |                         |                         |                         |         |
| No                      | 63 (98.4%)              | 31 (96.9%)              | 32 (100.0%)             | .313    |
| Yes                     | 1 (1.6%)                | 1 (3.1%)                | 0                       |         |
| COPD†                   |                         |                         |                         |         |
| No                      | 63 (98.4%)              | 31 (96.9%)              | 32 (100.0%)             | .313    |
| Yes                     | 1 (1.6%)                | 1 (3.1%)                | 0                       |         |

* Significant results (\( P \) value < .05).

† Chronic obstructive pulmonary disease.

3.2. Clinical characteristics and duration of stay in hospital

The most frequently reported clinical symptoms in COVID-19 patients with pulmonary fibrosis on admission were shortness of breath (98%), cough (91%), fever (70%), sputum (19%), and chest pain (16%); a small percentage of patients reported having diarrhea (6%) and a loss of smell (3%) (Table 2). Most COVID-19 patients with pulmonary fibrosis (81%) were admitted to ICU, and 19% were admitted to an isolation room in the general medical ward (Table 2). Sixty-three per cent and 22% of admitted COVID-19 patients with pulmonary fibrosis required mechanical ventilation and high-flow nasal cannula, respectively. All deceased patients (100%) were admitted to ICU and intubated (Table 2). The median duration between hospital admission and recovery was 20 days, while the median duration from hospital admission to death was 18 days. Fifty-six per cent of COVID-19 patients with pulmonary fibrosis did not have associated complications. In those who did, significant complications included respiratory failure (94%), sepsis (56%), and acute kidney injury (44%), which led to death (\( P < .001 \)).

### Table 2

| Symptoms and signs             | Overall (\( N = 64 \)) | Survived (\( N = 32 \)) | Deceased (\( N = 32 \)) | \( P \) |
|-------------------------------|-------------------------|-------------------------|-------------------------|---------|
| Difficulty breathing          | 63 (98.4%)              | 31 (96.9%)              | 32 (100%)               | .313    |
| Cough                         | 58 (90.6%)              | 30 (93.8%)              | 28 (87.5%)              | .391    |
| Sputum                        | 12 (18.8%)              | 12 (37.5%)              | 0                       | \(< .001 \)* |
| Hemoptysis                    | 1 (1.6%)                | 1 (3.1%)                | 0                       | .313    |
| Fever                         | 45 (70.3%)              | 21 (65.6%)              | 24 (75.0%)              | .412    |
| Chest pain                    | 10 (15.6%)              | 6 (18.8%)               | 4 (12.5%)               | .599    |
| Diaphoresis                   | 4 (6.2%)                | 2 (6.2%)                | 2 (6.2%)                | .999    |
| Loss of smell                 | 2 (3.1%)                | 2 (6.2%)                | 0                       | .151    |
| Low SpO2 (<95%)               | 42 (65.6%)              | 18 (56.2%)              | 24 (75.0%)              | .114    |
| PaO2/FIO2 (<100)              | 32 (50.0%)              | 13 (40.6%)              | 19 (69.4%)              | .251    |
| Isolation ward admission      | 12 (18.8%)              | 12 (37.5%)              | 0                       | \(< .001 \)* |
| ICU admission†                | 52 (81.2%)              | 20 (62.5%)              | 32 (100%)               | \(< .001 \)* |
| Mechanical ventilation        | 40 (62.5%)              | 8 (25.0%)               | 32 (100%)               | \(< .001 \)* |
| High flow nasal cannula       | 14 (21.9%)              | 14 (43.8%)              | 0                       | \(< .001 \)* |

* Significant results (\( P \) value < .05).

† Intensive care unit.
who later died compared with those who recovered. Compared with survivors, leukocytosis and neutrophilia concentrations were higher in patients who later demised (Table 3). In addition, levels of D-lactic and ferritin were higher in patients who later died compared with those who recovered (Table 3).

3.4. Radiological findings and dyspnea degree in recovered patients

The CT scans and chest X-rays revealed bilateral lung infiltrates in most of the COVID-19 patients with pulmonary fibrosis who recovered (94%). “Ground glass” opacity (91%), “honeycomb” lung (25%), and pulmonary consolidation (9%) were observed on the CT scans of these patients.

The overall mean CT scores of the patients at discharge and at the 6-month follow-up were 12.9 and 2.4, respectively. At the 6-month follow-up (Table 4), the CT score was significantly higher in patients with “ground glass” opacity, “honeycomb” lung, and pulmonary consolidation (P <.001, and P <.001, respectively) (Table 4). The CT scores at discharge and at the 6-month follow-up were significantly higher for severe cases admitted to the ICU and those requiring mechanical ventilation, compared with patients in the medical ward (P <.001 and P =.010, respectively) (Table 4). Associations between the CT scores at discharge and other variables, such as length of hospital stay, dyspnea scale, and the laboratory findings, were also evaluated. Higher CT scores were demonstrated to significantly correlate with a lengthy stay in hospital (P =.029, r =.393) and a greater degree of dyspnea (P =.001, r =.578); however, an association was not found between the CT scores and the laboratory findings.

The overall mean dyspnea scales for recovered patients at discharge and at the 6-month follow-up were 2.8 and 1.1, respectively. The mean dyspnea scale at 6 months was significantly higher in patients with bilateral lung infiltrates and “honeycomb” lung (P =.002 and P =.048, respectively) (Table 5). The dyspnea scales at discharge were also significantly higher in severe cases admitted to the ICU, compared with those admitted to the medical ward (P =.025) (Table 5). Typically, patients with a high degree of dyspnea at discharge required long-term oxygen therapy (P =.024) (Table 5). Half of the COVID-19 patients with pulmonary fibrosis (50%) who recovered required oxygen therapy, and those with “honeycomb” lung required long-term oxygen therapy to a considerably greater extent than others (P <.01).

### Table 3
Clinical laboratory findings adjusted for age, sex, and BMI.

| Lab Test                  | Overall (N=64) | Survived (N=32) | Deceased (N=32) | P     |
|---------------------------|----------------|-----------------|-----------------|-------|
| Hemoglobin, mmol/L        | 12.6±1.8       | 12.4±1.8        | 8.9±2.9         | .001  |
| White blood cell (×10^9/L)| 8.2±4.2        | 8.1±4.0         | 22.3±11.5       | .001  |
| Neutrophils (%)           | 6.6±4.1        | 6.3±4.1         | 85.6±9.1        | .001  |
| Lymphocytes (%)           | 1.6±2.1        | 1.9±2.8         | 9.7±10.1        | .149  |
| C-reactive protein, mg/L  | 7.6±5.1        | 8.2±6.4         | 4.9±5.1         | .149  |
| ESR†, mm/h                | 75.2±31.3      | 76.1±30.4       | 64.7±63.9       | .522  |
| D-dimer, mcg/mL           | 3.1±7.5        | 2.7±6.5         | 7.6±6.4         | .008  |
| Serum ferritin, pmol/mL   | 753±696        | 738±658         | 1674±1860       | .027  |

* Significant results (P value <.05).
† Erythrocyte sedimentation rate.

### Table 4
CT scores in survived COVID-19 patients with pulmonary fibrosis during follow up.

| Variable                        | At discharge | 1st month | 3rd month | 6th month |
|---------------------------------|--------------|-----------|-----------|-----------|
| Bilateral lung infiltrations    |              |           |           |           |
| No                              | 11.1±2.5     | 6.5±1.8   | 2.8±1.2   | 1.6±0.8   | .001†    |
| Yes                             | 13.8±1.1     | 8.2±0.8   | 3.5±0.8   | 2.6±0.5   | .001†    |
| P                               | .272         | .367      | .684      | .414      |          |
| Ground-glass opacity            |              |           |           |           |
| No                              | 12.7±1.0     | 7.7±0.8   | 3.0±0.7   | 2.0±0.4   | .001†    |
| Yes                             | 18.7±2.9     | 9.3±1.8   | 7.0±2.1   | 5.3±2.7   | .001†    |
| P                               | .081         | .522      | .068      | .036†     |          |
| Honeycomb                       |              |           |           |           |
| No                              | 12.4±1.3     | 6.7±0.8   | 2.0±0.6   | 1.3±0.4   | .001†    |
| Yes                             | 15.9±0.7     | 11.4±0.8  | 7.3±0.8   | 5.6±0.7   | .001†    |
| P                               | .132         | .003*     | <.001†    | <.001†    |          |
| Consolidation                   |              |           |           |           |
| No                              | 12.9±1.1     | 7.5±0.8   | 2.8±0.6   | 1.8±0.4   | .001†    |
| Yes                             | 16.3±1.2     | 11.3±0.7  | 9.3±0.7   | 7.3±0.7   | .001†    |
| P                               | .329         | .123      | .001†     | <.001†    |          |
| ICU admission                   |              |           |           |           |
| No                              | 9.0±1.6      | 4.6±0.6   | 1.5±0.6   | 0.7±0.5   | .001†    |
| Yes                             | 15.8±0.9     | 9.9±0.8   | 4.6±0.9   | 3.3±0.6   | .001†    |
| P                               | <.001†       | <.001†    | <.018†    | .01†      |          |
| Mechanical ventilation          |              |           |           |           |
| No                              | 11.8±1.1     | 6.8±0.7   | 2.5±0.6   | 1.6±0.4   | .001†    |
| Yes                             | 17.6±1.3     | 11.7±1.5  | 6.4±1.5   | 4.6±1.0   | .001†    |
| P                               | .009†        | .003      | .009†     | .003†     |          |
| High flow nasal canula          |              |           |           |           |
| No                              | 12.8±1.5     | 7.5±1.1   | 3.2±0.9   | 2.4±0.7   | .001†    |
| Yes                             | 13.8±1.2     | 8.4±0.9   | 3.3±0.9   | 2.3±0.6   | .001†    |
| P                               | .644         | .542      | .890      | .917      |          |
| Long term oxygen therapy        |              |           |           |           |
| No                              | 12.1±1.5     | 6.1±0.8   | 2.0±0.8   | 1.6±0.5   | .001†    |
| Yes                             | 14.6±1.3     | 9.6±1.1   | 4.7±0.9   | 3.1±0.7   | .001†    |
| P                               | .210         | .014†     | .037†     | .054†     |          |

* Significant results (P value <.05).
† P value of independent sample t test.

3.5. Predictors of ICU admission and mortality risk using Cox regression analysis

The multivariate Cox proportional hazards regression model revealed statistically significant findings (P <.001); it is provided in Table 6. It revealed that the mortality risk increased with smoking (HR 2.8 [95% CI 1.6–4.9]; P <.001) and that the risk was significantly more than twofold higher in smoker patients than in non-smokers (Table 6). The mortality risk in COVID-19 patients with pulmonary fibrosis and asthma was more than threefold higher than in the others HR 3.1 [95% CI 1.0–9.4]; P =.001) (Table 6). Obesity (HR 1.1 [95% CI 1.0–1.2]; P =.012) was also significant risk factors associated with mortality in COVID-19 patients with pulmonary fibrosis (Table 6). The mortality risk was notably higher in patients who developed sepsis (HR 2.3 [95% CI 1.2–4.7]; P =.017) and acute kidney injury (HR 4.7 [95% CI 2.2–9.9]; P =.001); these patients had a 2.3- and 4.5-fold higher mortality risk respectively than those without any complications (Table 6). Smoking (HR 1.5 [95% CI 1.0–2.1]; P =.026), asthma (HR 2.7 [95% CI 1.1–6.7]; P =.033), and acute kidney injury (HR 3.2 [95% CI 1.6–6.8]; P =.012) were also significant risk factors associated with ICU admission in COVID-19 patients with pulmonary fibrosis (Table 6).
Table 5

Dyspnea scores in survived COVID-19 patients with pulmonary fibrosis during follow up.

| Variable                  | At discharge | 1st month | 3rd month | 6th month |
|---------------------------|--------------|-----------|-----------|-----------|
| Bilateral lung infiltrations | 2.8 ± 0.1    | 1.9 ± 0.1 | 1.5 ± 0.1 | 1.0 ± 0.1 |
| No                        |             | .946      | .086      | .850      | .002*     |
| Yes                       | 2.8 ± 0.1   | .419      | .998      | .476      | .554      |
| Ground-glass opacity       | 2.8 ± 0.1   | 2.0 ± 0.1 | 1.3 ± 0.3 | 1.0 ± 0.1 |
| No                        |             | .142      | .722      | .022*     | .048*     |
| Yes                       | 3.0 ± 0.1   | .419      | .928      | .094      | .398      |
| Consolidation              | 2.8 ± 0.1   | 2.0 ± 0.1 | 1.5 ± 0.1 | 1.1 ± 0.1 |
| No                        |             | .142      | .722      | .022*     | .048*     |
| Yes                       | 3.0 ± 0.1   | .419      | .928      | .094      | .398      |
| ICU admission              | 2.6 ± 0.1   | 1.9 ± 0.1 | 1.3 ± 0.2 | 1.1 ± 0.1 |
| No                        |             | .024*     | .147      | .150      | .599      |
| Yes                       | 2.9 ± 0.2   | .283      | .917      | .754      | .971      |
| Mechanical ventilation     | 2.8 ± 0.1   | 2.0 ± 0.1 | 1.5 ± 0.1 | 1.1 ± 0.1 |
| No                        |             | .142      | .722      | .022*     | .048*     |
| Yes                       | 3.0 ± 0.1   | .419      | .928      | .094      | .398      |
| High flow nasal canula     | 2.8 ± 0.1   | 2.0 ± 0.1 | 1.5 ± 0.2 | 1.1 ± 0.1 |
| No                        |             | .142      | .722      | .022*     | .048*     |
| Yes                       | 2.9 ± 0.1   | .283      | .917      | .754      | .971      |
| Long term oxygen therapy   | 2.7 ± 0.1   | 1.9 ± 0.1 | 1.4 ± 0.1 | 1.1 ± 0.1 |
| No                        |             | .024*     | .168      | .061      | .370      |
| Yes                       | 2.9 ± 0.1   | .283      | .917      | .754      | .971      |

* Significant results (P value < .05).
† P value of independent sample t test.

4. Discussion

The development of pulmonary fibrosis is a rare complication of COVID-19. The objective of the current study was to address the gap in knowledge regarding the clinical characteristics and outcomes of patients who developed pulmonary fibrosis after infection with COVID-19 and hospitalized at King Fahad Central Hospital, Jazan Province, Saudi Arabia.

Advanced age was identified as a significant risk factor for the development of pulmonary fibrosis post-COVID-19.[21] Similarly, a finding of pulmonary fibrosis correlated with age in cases of severe acute respiratory syndrome. In the current study, recovered COVID-19 patients with pulmonary fibrosis had a mean age of 56 years, and the deceased patients had a mean age of 62 years. In previous studies,[22,23] it was established that elderly patients with viral pneumonia, including Middle East Respiratory Syndrome and COVID-19, were more likely to develop pulmonary fibrosis. In addition, old age has been confirmed to be associated with poor outcomes in COVID-19 patients.[24] With advanced age, cell-mediated immunity and the humoral immune response decrease, and this can result in poor control of viral replication and extensive inflammatory responses, potentially leading to poor outcomes.[25,26]

In the current study, a greater proportion of male COVID-19 patients had pulmonary fibrosis (72%) compared with female patients (28%). In addition, a higher number of male patients (62%), relative to the number of female patients (37%), died of COVID-19. Hossain et al[24] reported that survival was significantly higher in female patients than in male patients (P < .001). This may be explained by the effect of androgen, which promotes the transcription of transmembrane serine protease 2, a protein-coding gene that impairs the antibody response to acute respiratory syndrome coronavirus 2, thereby enhancing fusion of the virus and host cells.[27]

Smoking has been linked to the pathogenesis of various lung diseases, including chronic obstructive pulmonary disease and pulmonary fibrosis.[28] Smoking history was also identified in the current study as a risk factor for pulmonary fibrosis in post-COVID-19 patients. The present study showed that smokers were more likely to develop severe pulmonary fibrosis post-COVID-19 than non-smokers, and it was a predictor of mortality since smoking leads to oxidative stress and increased mucosal inflammation and inflammatory cytokines results in severe symptoms.[28]

Elsewhere, associated comorbidities, such as hypertension, diabetes, and coronary artery disease, have been associated with

Table 6

Predictors of mortality and intensive care admission in COVID-19 patients with pulmonary fibrosis.

| Predictors                  | ICU admission | Mortality |
|-----------------------------|---------------|-----------|
|                             | HR            | 95% CI    | P-value | HR            | 95% CI    | P-value |
| Age                         | 1.0           | 0.9–1.2   | .742    | 1.0           | 0.9–1.4   | .107    |
| Sex                         | 1.1           | 0.5–1.9   | .877    | 1.1           | 0.2–3.2   | .844    |
| Smoking                     | 1.5           | 1.0–2.1   | .026*   | 2.8           | 1.6–4.9   | <.001*  |
| Comorbidities               |               |           |         |               |           |         |
| Hypertension                | 1.4           | 0.6–2.9   | .433    | 2.7           | 0.9–5.7   | .089    |
| Diabetes                    | 1.8           | 0.3–2.8   | .071    | 1.1           | 0.4–2.5   | .954    |
| Cardiovascular disease      | 1.3           | 0.4–4.3   | .590    | 1.0           | 0.3–1.7   | .112    |
| Kidney disease              | 1.5           | 0.3–8.4   | .657    | 2.5           | 0.6–3.1   | .392    |
| Obesity                     | 1.2           | 0.6–2.4   | .517    | 1.1           | 1.0–1.2   | .012*   |
| Asthma                      | 2.7           | 1.1–6.7   | .033*   | 3.1           | 1.0–9.4   | .001*   |
| Associated complications    |               |           |         |               |           |         |
| Sepsis                      | 2.2           | 0.4–2.9   | .089    | 2.3           | 1.2–4.7   | .017*   |
| Acute kidney injury         | 3.2           | 1.6–6.8   | .001*   | 4.7           | 2.2–9.9   | .001*   |

* Comorbidities adjusted for one another + age, BMI, and sex; Lab investigations were adjusted for age, BMI, and sex; significant results (P value < .05).
an increase in disease severity in COVID-19 patients.\textsuperscript{[29]} In the current study, diabetes and hypertension accounted for 65% of COVID-19 patients with pulmonary fibrosis, and the laboratory findings showed that lymphopenia, leukocytosis, and neutrophilia were observed 24 hours prior to patient deaths. These findings correlate with the increase in disease severity reported in a previous study.\textsuperscript{[30]} In other research, an elevation in serum cytokines were observed 24 hours prior to patient deaths. These findings correlate with the increase in disease severity reported in a previous study.

Bronchial asthma was identified in 15% of the participants in the current study, and it was shown to be a significant risk factor for mortality in COVID-19 patients with pulmonary fibrosis. The risk of mortality was twice as great in COVID-19 patients with pulmonary fibrosis and asthma than in other patients. Pulmonary fibrosis primarily develops around the alveoli; however, fibrosis in the lungs, along with asthma, causes thickening of the airway walls that may increase disease severity and worsen outcomes.\textsuperscript{[31]}

Severe COVID-19 cases may require ICU admission, and this, in combination with mechanical ventilation, is a risk factor for the development of pulmonary fibrosis, especially with a lengthy ICU stay. A significant relationship has been observed between mechanical ventilation and development of pulmonary fibrosis.\textsuperscript{[32]} In the current study, 81% of the hospitalized COVID-19 patients were admitted to the ICU, and 62% required intubation and mechanical ventilation. In general, the need for mechanical ventilation is closely linked to ventilator-induced lung injury.\textsuperscript{[33]}

It has been shown that the prolonged use of mechanical ventilation leads to the release of proinflammatory cytokines with severe lung injury, which increases the risk of mortality and the development of pulmonary fibrosis.\textsuperscript{[33]}

Clinically, in the present study, despite a general improvement in the degree of dyspnea among COVID-19 patients with pulmonary fibrosis, dyspnea was seen to persist in some patients until 6 months post discharge. This supports the finding of a previous study conducted in Italy that reported the persistence of dyspnea in 43% of patients for months after discharge from hospital.\textsuperscript{[34]}

A chest CT was used in the current study to diagnose post-COVID-19 pulmonary fibrosis and during follow-ups. In this regard, “ground glass” opacity, “honeycomb” lung, and pulmonary consolidation were the most common CT findings. Francone et al.\textsuperscript{[35]} reported that “ground glass” opacity was predominant in the early phase (≤7 days) of the onset of COVID-19 symptoms, while pulmonary consolidation and fibrosis characterized late-phase disease (>7 days). In the current study, the overall mean CT scores of the recovered patients improved over a 6-month period (i.e., scores of 12.9 and 2.4 at discharge and 6 months). The CT score correlated highly with disease severity, and it was useful for predicting the outcomes of COVID-19 patients and mortality risk.\textsuperscript{[35]} It was observed that the CT scores at discharge and at the 6-month follow-up were significantly higher in severe cases admitted to the ICU and who required mechanical ventilation, compared with patients in the medical ward ($P \leq .001$ and $P = .010$, respectively). These results are consistent with the findings of a previous study.\textsuperscript{[35]} Further analysis established an association between the CT score, duration of hospitalization, and the degree of dyspnea. It is well-known that radiographical abnormalities strongly correlate with the long-term impairment of lung function.\textsuperscript{[36]} Zuo et al.\textsuperscript{[37]} also demonstrated a correlation between the degree of pulmonary fibrosis and the duration of COVID-19 disease. Clinical data have shown that fibrotic organization was more common in patients in the late stages, rather than in the early stages, of pneumonia.\textsuperscript{[38]}

For the management in the present study of post-COVID-19 pulmonary fibrosis, prednisolone was prescribed as the first-line treatment, with gradual tapering of the dose, and it was associated with an improvement in the symptoms of the recovered patients. Corticosteroids have an anti-inflammatory action and are effective in the fibroproliferative phase of ARDS.\textsuperscript{[33–41]} They remain part of the management of the usual interstitial pneumonia. Early treatment with corticosteroids is well-tolerated in patients with post-COVID-19 pulmonary fibrosis and is associated with a rapid and significant improvement in well-being.\textsuperscript{[42]} A few case reports documented that antifibrotic agents, for example, pirfenidone and nintedanib, were effective in treating post-COVID-19 pulmonary fibrosis.\textsuperscript{[43–45]} At present, there is no approved treatment for the management of post-COVID-19 pulmonary fibrosis. Thus, more clinical trials are warranted to identify the most suitable treatment approach to this disease.

5. Conclusion

Post-COVID-19 pulmonary fibrosis is a severe complication that leads to permanent lung damage or death. Early detection may help to prevent or at least delay its development.

Author contributions

Conceptualization: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim, Murad Hamood Sadhan, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Data curation: Shereen Farghaly, Mohammed Badedi, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Formal analysis: Shereen Farghaly, Mohammed Badedi, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Funding acquisition: Shereen Farghaly.

Investigation: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim, Awaji Alnami, Abdulrahman Muhajir.

Methodology: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim, Murad Hamood Sadhan, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Project administration: Shereen Farghaly.

Resources: Shereen Farghaly, Mohammed Badedi.

Software: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim.

Supervision: Shereen Farghaly, Mohammed Badedi.

Validation: Shereen Farghaly, Mohammed Badedi, Murad Hamood Sadhan, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Visualization: Shereen Farghaly, Mohammed Badedi, Murad Hamood Sadhan.

Writing – original draft: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim, Murad Hamood Sadhan, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

Writing – review & editing: Shereen Farghaly, Mohammed Badedi, Rehab Ibrahim, Murad Hamood Sadhan, Aymn Alamoudi, Awaji Alnami, Abdulrahman Muhajir.

References

[1] Moore B, Moore T. Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation. Am Am Thorac Soc 2015;12(suppl):S186–92.
[2] Raghu G, Weckesser D, Edelberg J, Bradford W, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810–6.

[3] Abramson M, Murambadze T, Alif S, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study. Thorax 2020;75:864–9.

[4] Naik PK, Moore BB. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med 2010;4:759–71.

[5] Bharat A, Quersey M, Markov N, et al. Lung transplantation for pulmonary fibrosis secondary to severe COVID-19. medRxiv 2020;2020.10.26.2018636. doi: 10.1101/2020.10.26.2018636. Update in: Sci Transl Med. 2020;12.

[6] Udawadi Z, Pokharniyal P, Tripathi A, Kohli A. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India 2021;38:61–3.

[7] Carfi A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group Persisting symptoms in patients after acute COVID-19. JAMA 2020;324:603–5.

[8] George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med 2019;7:271–82.

[9] Ali R, Ghonimy M. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequela in surviving patients. Egypt J Radiol Nucl Med 2021;52:101.

[10] Rai D, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat? Indian J Tuberc. 2021;68:330–3.

[11] McGroder C, Zhang D, Choudhury M, et al. Pulmonary characteristics of deceased COVID-19 patients. Int J Environ Res Public Health 2021;18:10133.

[12] Badedi M, Darraj H, Hummadi A, et al. Diabetes-related distress and diabetes mellitus. Diabetes Metab Syndr Obes 2020;13:307–12.

[13] Alzughbi T, Badedi M, Darraj H, et al. Diabetes-related distress and depression in Saudis with type 2 diabetes. Psychol Res Behav Manag 2020;13:453–8.

[14] Badedi M, Darraj H, Hummadi A, et al. Vitamin B12 deficiency and foot ulcers in type 2 diabetes mellitus: a case-control study. Diabetes Metab Syndr Obes 2019;12:2589–96.

[15] Saudi Center for Disease Prevention and Control. (Wataya). Laboratory Diagnosis of COVID-19 in Suspected Cases. Available at: https://covid19.moh.gov.sa/professionals-health-workers/laboratory-diagnosis/. Accessed Oct 12, 2020.

[16] World Health Organization (WHO). Corticosteroid for COVID-19. Geneva: WHO; 2020.

[17] Saudi Center for Disease Prevention and Control. COVID-19 Guidelines. Riyadh; 2020.

[18] Demeds M, Costabel U. ATVers international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 2002;19:794–6.

[19] Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol 2020;30:4407–16.

[20] Saudi Ministry of Health. Protocol for Patients Suspected of/Confirmed with COVID-19. Available at: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOH-therapeutic-protocol-for-COVID-19.pdf.

[21] Richeldi L, Collard H, Jones M. Idiopathic pulmonary fibrosis. Lancet 2017;389:1941–52.

[22] Wong K, Antonio G, Hui D, et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J Comput Assist Tomogr 2002;28:790–5.

[23] Sansone A, Mollaioi D, Ciocca G, et al. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J Endocrinol Invest 2021;44:223–31.

[24] Hossain I, Tuhin S, Mullick A, et al. Clinical course, risk factors and health outcome of in patients with COVID-19: an evidence from COVID-19 dedicated Mgdua Medical College and Hospital in Bangladesh. JMSCR 2020;8.

[25] Kalil A, Metersky M, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infections Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:61–111.

[26] Zhou F. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. J Med Stud Res 2020;3:15.

[27] Lee E, Singh R. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 2017;27:342–9.

[28] Strelazek A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health 2018;15:1033.

[29] Badedi M, Makrami A, Alnami A. Co-morbidity and blood type group risk in coronavirus disease 2019 patients: a case-control study. J Infect Public Health 2021;14:530–4.

[30] Badedi M, Darraj H, Alnami A, et al. Epidemiological characteristics and deceased COVID-19 patients. Int J Gen Med 2021;14:3809–19.

[31] Schmidt M, Sun G, Stacey M, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380–9.

[32] Desai SR, Wells AU, Rubens MB, Evans TW, Hansell DM. Acute respiratory distress syndrome: CT abnormalities at long-term follow-up. Radiology 1999;210:29–35.

[33] Oeckler RA, Hubmayr RD. Ventilator-associated lung injury: a search for better therapeutic targets. Eur Respir J 2007;30:1216–26.

[34] Carfi A, Bernabei R, Landi F. For the Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. J Am Med Assoc 2020;324:603–5.

[35] Francone M, Iafarto F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020;30:6808–17.

[36] Burnham EL, Hyzy RC, Paine R, Coley C, Kelly AM, Quint LE. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit Care Med 2013;41:445–56.

[37] Zuo W, Zhao X, Chen Y, Lal SK. SARS coronavirus and lung fibrosis. Molecular Biology of the SARS-Coronavirus Berlin/Heidelberg, Germany: Springer; 2010:247–58.

[38] Hwang D, Chamberlain D, Poutanen S, Low D, Assa S, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 2005;18:1–10.

[39] American Thoracic Society (ATS), European Respiratory Society (ERS). Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000;161:646–64.

[40] Biff L, Moore F, Moore E, Haenel J, McIntyre RJr, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995;170:591–6.

[41] Raghavendran K, Pryhuber G, Chess P, Davidson B, Knight P, Notter R. Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem 2008;15:1911–24.

[42] Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. an observational study of corticosteroid treatment. Ann Am Thorac Soc 2021;18:799–806.

[43] Xi Z, Zhigang Z, Ting L. “Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: effectively treated with Pirfenidone”. Arch Pulmonol Respir Care 2020;6:51–3.

[44] Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. Respirol Case Rep 2021;9:e00744.

[45] Chakrabortty R, Rahman S, Jahan R, Dip AH, Rahman MM. Nintedanib in the management of pulmonary fibrosis after COVID-19: a case report. BIRDEM Med J 2021;11:148–52.